---
layout: post
title: "人福医药：注射用苯磺酸瑞马唑仑增加适应症获得药品注册证书"
date: 2022-03-16 16:19:10 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600079" data-code="600079|1|1" data-code2="600079|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600079&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600079_0" data-code="K 600079|1|1" data-code2="K 600079|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>人福医药(600079)3月16日晚间公告，控股子公司宜昌人福近日收到国家药品监督管理局核准签发的关于注射用苯磺酸瑞马唑仑增加适应症的《药品注册证书》。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203162312134554>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)